Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
New fundamentals in hemostasis.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH.
Physiol Rev. 2013 Jan;93(1):327-58. doi: 10.1152/physrev.00016.2011.
Coagulation Testing in the Core Laboratory.
Winter WE, Flax SD, Harris NS.
Lab Med. 2017 Nov 8;48(4):295-313. doi: 10.1093/labmed/lmx050.
Continuous infusion of coagulation factor concentrates during intensive treatment.
Holme PA, Tjønnfjord GE, Batorova A.
Haemophilia. 2018 Jan;24(1):24-32. doi: 10.1111/hae.13331. Epub 2017 Sep 5.
Pearls and pitfalls in factor inhibitor assays.
Adcock DM, Favaloro EJ.
Int J Lab Hematol. 2015 May;37 Suppl 1:52-60. doi: 10.1111/ijlh.12352.
Advances in monitoring anticoagulant therapy.
Božič Mijovski M.
Adv Clin Chem. 2019;90:197-213. doi: 10.1016/bs.acc.2019.01.005. Epub 2019 Feb 21.
Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy.
Cugno M, Gualtierotti R, Tedeschi A, Meroni PL.
Autoimmun Rev. 2014 Jan;13(1):40-8. doi: 10.1016/j.autrev.2013.08.001. Epub 2013 Aug 14.
Protein C activation.
Esmon CT, Esmon NL.
Semin Thromb Hemost. 1984 Apr;10(2):122-30. doi: 10.1055/s-2007-1004414.
The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M, Mannucci PM.
Expert Opin Drug Saf. 2016 Oct;15(10):1391-400. doi: 10.1080/14740338.2016.1208747. Epub 2016 Jul 18.
The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation.
Rapaport SI.
Thromb Haemost. 1991 Jul 12;66(1):6-15.
Lupus anticoagulant.
[No authors listed]
Lancet. 1984 May 26;1(8387):1157-8.
